2. Search Result
Search Result
Results for "

WT BALB/cJ mice

" in MedChemExpress (MCE) Product Catalog:

2918

Inhibitors & Agonists

1

Screening Libraries

18

Fluorescent Dye

35

Biochemical Assay Reagents

199

Peptides

1

MCE Kits

82

Inhibitory Antibodies

420

Natural
Products

30

Recombinant Proteins

83

Isotope-Labeled Compounds

9

Antibodies

16

Click Chemistry

37

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10797
    CJ-42794
    2 Publications Verification

    cJ-042794

    		 Prostaglandin Receptor Inflammation/Immunology Endocrinology
    CJ-42794 (CJ-042794) is a potent, orally active, selective prostaglandin E receptor 4 (EP4) antagonist with an IC50 value of 10 nM, which is 200-fold more selective than EP1, EP2 and EP3. CJ-42794 can be used in research of gastric ulcers .
    CJ-42794
  • HY-17623
    Tegoprazan
    2 Publications Verification

    cJ-12420; RQ-00000004

    		 Proton Pump Potassium Channel Na+/K+ ATPase Inflammation/Immunology
    Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a reversible, orally active and highly selective inhibitor of gastric H +/K +-ATPase. Tegoprazan inhibits gastric acid secretion and motility against porcine, canine and human H +/K +-ATPase with IC50 values ranging from 0.29-0.52 μM in vitro. Tegoprazan significantly improves colitis and enhances the intestinal epithelial barrier function in mice. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
    Tegoprazan
  • HY-106200
    CJ-13,610

    		Lipoxygenase Inflammation/Immunology
    CJ-13,610, a nonredox-type 5-LO inhibitor, dose dependently suppresses 5-LO product formation in ionophore A23187-stimulated PMNL in the absence of exogenous AA with an IC50 of about 70 nM . PMNL: polymorphonuclear leukocytes; AA: arachidonic acid
    CJ-13,610
  • HY-103108
    CJ033466

    		5-HT Receptor Metabolic Disease
    CJ033466 is a novel and selective 5-HT4 receptor partial agonist with an EC50 of 9 nM and has gastroprokinetic effect .
    CJ033466
  • HY-117881
    CJ-15208

    		Opioid Receptor Neurological Disease
    CJ-15208 is a potent and selective κ-opioid receptor antagonist with significant opioid activity. CJ-15208 exhibited strong analgesic effects in the warm water tail withdrawal test in mice and was mediated through multiple opioid receptors. The stereoisomers of CJ-15208 exhibited different opioid activity characteristics, for example, one stereoisomer exhibited κ-opioid receptor antagonism, while the other exhibited δ-opioid receptor antagonism. All stereoisomers of CJ-15208 had no significant effects on respiration. The stereoisomers of CJ-15208 did not lead to the development of drug tolerance, which makes it potential in the further development of safe opioid analgesics .
    CJ-15208
  • HY-123191
    CJ-463

    		PAI-1 Cancer
    CJ-463 is a potent and selective uPA inhibitor. CJ-463 has antitumor activity .
    CJ-463
  • HY-N7188
    CJ-21,058

    		Bacterial Infection
    CJ-21,058 is a potent SecA inhibitor with an IC50 value of 15 µg/mL. CJ-21,058 inhibits ATP-dependent translocation of precursor proteins across a bacterial cell membrane. CJ-21,058 shows antibacterial activity against Gram-positive bacteria .
    CJ-21,058
  • HY-106200A
    CJ-13,610 hydrochloride

    		Lipoxygenase Cardiovascular Disease Inflammation/Immunology Cancer
    CJ-13,610 (hydrochloride) is an orally active and potent nonredox-type 5-lipoxygenase inhibitor with an IC50 value of 0.07 μM. CJ-13,610 (hydrochloride) competes with activating LOOH at a regulatory LOOH-binding site with high affinity, thereby preventing 5-lipoxygenase catalysis. CJ-13,610 (hydrochloride) is promising for research of diseases related to elevated levels of 5-lipoxygenase such as inflammatory reactions, allergic asthma, various types of cancer and atherosclerosis .
    CJ-13,610 hydrochloride
  • HY-157528
    CJ28

    		Endogenous Metabolite Cancer
    CJ28 is a cortisol biosynthesis inhibitor that significantly inhibits basal and stimulated cortisol production in human adrenal carcinoma cell lines. CJ28 exhibits inhibitory effects by reducing steroidogenesis and de novo cholesterol biosynthesis .
    CJ28
  • HY-131909
    CJ-2360

    		Anaplastic lymphoma kinase (ALK) Cancer
    CJ-2360 is a potent and orally active ALK inhibitor with IC50s of 2.2, 4.0, 8.8, 6.3, and 8.9 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively. CJ-2360 displays potent inhibitory activity against two clinically reported ALK mutants (C1156Y and L1196M) and a few other kinases (LTK, MERTK, CLK1, DAPK1, and DAPK2) among the 468 kinases evaluated .
    CJ-2360
  • HY-106982
    Ezlopitant

    cJ-11,974

    		 Neurokinin Receptor Neurological Disease Metabolic Disease
    Ezlopitant (CJ-11,974) is a selective, non-peptidic neurokinin-1 (NK-1)-receptor antagonist. Ezlopitant inhibits both acute and delayed emetic reactions induced by Cisplatin (HY-17394) in ferrets via acting on NK1 receptors in the central nervous system. Ezlopitant has the potential for pain, chemotherapy-induced emesis and irritable bowel syndrome research .
    Ezlopitant
  • HY-100871
    WT-161
    5+ Cited Publications

    		 Beta-lactamase HDAC Apoptosis Cancer
    WT-161 is a potent and selective HDAC6 inhibitor with an IC50 of 0.40 nM . WT-161 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) .
    WT-161
  • HY-16781
    Grapiprant
    4 Publications Verification

    cJ-023423; RQ-00000007; AAT-007

    		 Prostaglandin Receptor Metabolic Disease Endocrinology Cancer
    Grapiprant (CJ-023423) is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2). Grapiprant displaces [ 3H]-PGE2 (1 nM) binding to dog recombinant EP4 receptor with IC50 value of 35 nM and Ki value of 24 nM. Grapiprant has the potential for osteoarthritic pain and inflammation treatment [3] .
    Grapiprant
  • HY-17623S
    Tegoprazan-d6

    cJ-12420-d6; RQ-00000004-d6

    		 Proton Pump Na+/K+ ATPase Metabolic Disease
    Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
    Tegoprazan-d6
  • HY-17623D
    Tegoprazan Benzoate

    cJ-12420 Benzoate; RQ-00000004 Benzoate

    		 Proton Pump Metabolic Disease
    Tegoprazan Benzoate is the benzoate form of Tegoprazan (HY-17623). Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H +/K +-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro .
    Tegoprazan Benzoate
  • HY-P6013
    wt hMLN

    		Calcium Channel Others
    wt hMLN is a microprotein that inhibits of SR Ca 2+ pump (SERCA). wt hMLN plays an important role in skeletal muscle calcium homeostasis .
    wt hMLN
  • HY-17623R
    Tegoprazan (Standard)

    cJ-12420 (Standard); RQ-00000004 (Standard)

    		 Reference Standards Proton Pump Metabolic Disease
    Tegoprazan (Standard) is the analytical standard of Tegoprazan. This product is intended for research and analytical applications. Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H +/K +-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro .
    Tegoprazan (Standard)
  • HY-P6013A
    wt hMLN TFA

    		Calcium Channel Others
    wt hMLN (TFA) is a microprotein that inhibits of SR Ca 2+ pump (SERCA). wt hMLN plays an important role in skeletal muscle calcium homeostasis .
    wt hMLN TFA
  • HY-17623C
    (R)-Tegoprazan

    (R)-cJ-12420; (R)-RQ-00000004

    		 Proton Pump Metabolic Disease
    (R)-Tegoprazan ((R)-CJ-12420; example 3), a benzimidazole derivative, is a potent kidney H +/K +-ATPase inhibitor with an IC50 of 98 nM of canine kidney Na +/K +-ATPase. (R)-Tegoprazan has the potential for gastrointestinal diseases research .
    (R)-Tegoprazan
  • HY-153577
    WT-TTR inhibitor 1

    		Transthyretin (TTR) Neurological Disease
    WT-TTR inhibitor 1 (Compound 21) is a wild-type Transthyretin (WT-TTR) inhibitor with 29.05% inhibition at 100 μM .
    WT-TTR inhibitor 1
  • HY-P1404
    R8-T198wt

    		Pim Cancer
    R8-T198wt is a cell-permeable carboxyl-terminal p27 Kip1 peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase .
    R8-T198wt
  • HY-163371
    EGFR WT/T790M-IN-1

    		EGFR Apoptosis Cancer
    EGFR WT/T790M-IN-1 (Compound 16h) is a dual EGFR WT and EGFR T790 inhibitor. EGFR WT/T790M-IN-1 can arrest the cell cycle in G2/M phase and induce apoptosis. EGFR WT/T790M-IN-1 has anti-cancer activity .
    EGFR WT/T790M-IN-1
  • HY-157994
    EGFR WT/T790M-IN-2

    		EGFR Apoptosis Cancer
    EGFR WT/T790M-IN-2 (Compound 7c) is a EGFR T790M/WT inhibitor with IC50 values of 0.08 and 0.13 μM, respectively. EGFR WT/T790M-IN-2 induces apoptosis by blocking the G0-G1 phase (apoptosis). EGFR WT/T790M-IN-2 has antitumor activity .
    EGFR WT/T790M-IN-2
  • HY-RS15853
    WT1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    WT1 Human Pre-designed siRNA Set A contains three designed siRNAs for WT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    WT1 Human Pre-designed siRNA Set A
    WT1 Human Pre-designed siRNA Set A
  • HY-RS23476
    Wt1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Wt1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Wt1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Wt1 Rat Pre-designed siRNA Set A
    Wt1 Rat Pre-designed siRNA Set A
  • HY-RS17032
    Wt1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Wt1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Wt1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Wt1 Mouse Pre-designed siRNA Set A
    Wt1 Mouse Pre-designed siRNA Set A
  • HY-162062
    EGFR WT/T790M/L858R-IN-1

    		EGFR Cancer
    EGFR WT/T790M/L858R-IN-1 (compound 10d) is a potent EGFR inhibitor, with IC50s of 0.097, 0.280, and 0.051?μM for EGFR WT, EGFR T790M, and EGFR L858R, respectively. EGFR WT/T790M/L858R-IN-1 can be used for the research of cancer .
    EGFR WT/T790M/L858R-IN-1
  • HY-146496
    Antitubercular agent-20

    		Bacterial Infection
    Antitubercular agent-20 (Compound 2d) is an orally active antitubercular agent. Antitubercular agent-20 shows excellent activity against MTB H37Rv and MDR-MTB strains (MIC: ＜0.016 µg/ml). Antitubercular agent-20 has low cytotoxicity and good tolerance in BALB/c mice .
    Antitubercular agent-20
  • HY-146495
    Antitubercular agent-19

    		Bacterial Infection
    Antitubercular agent-19 (Compound 1c) is an antitubercular agent. Antitubercular agent-19 shows excellent activity against MTB H37Rv and MDR-MTB strains (MIC: ＜0.016 µg/ml). Antitubercular agent-19 shows low cytotoxicity and relatively high acute lethal toxicity in BALB/c mice .
    Antitubercular agent-19
  • HY-157870
    Mtb-IN-6

    		Bacterial Infection
    Mtb-IN-6 (Compound C10) is a Mycobacterium tuberculosis(Mtb) respiration inhibitor. Mtb-IN-6 can enhance the bactericidal activity of isoniazid (INH, HY-B0329). Mtb-IN-6 inhibits WT Mtb with an IC50 of 25 µM .
    Mtb-IN-6
  • HY-169928
    WRN inhibitor 14

    		DNA/RNA Synthesis Cancer
    WRN inhibitor 14 (compound S35) is an orally active WRN inhibitor with anticancer activity. WRN inhibitor 14 results in tumor growth inhibition in the SW48 xenograft model in BALB/c nude mice .
    WRN inhibitor 14
  • HY-161065
    HKI12134085

    		Bacterial Infection
    HKI12134085 (compound 3) is an orally available antibacterial nitrobenzothiazinone (BTZ) derivative with activity against Mycobacterium tuberculosis. HKI12134085 has in vivo inhibitory potency in a BALB/c mouse model of Mycobacterium tuberculosis infection .
    HKI12134085
  • HY-159092
    HIV-1 integrase inhibitor 13

    		HIV Integrase Infection
    HIV-1 integrase inhibitor 13 (Compound 15) is an inhibitor for HIV-1 integrase with an IC50 of 1.8 nM. HIV-1 integrase inhibitor 13 inhibits the HIV-1 WT and HIV-1 T125A, with IC50 of 21 and 580 nM, respectively .
    HIV-1 integrase inhibitor 13
  • HY-159091
    HIV-1 integrase inhibitor 12

    		HIV Integrase Infection
    HIV-1 integrase inhibitor 12 (Compound 17) is an inhibitor for HIV-1 integrase with an IC50 of 1.4 nM. HIV-1 integrase inhibitor 12 inhibits the HIV-1 WT and HIV-1 T125A, with IC50 of 7.4 and 120 nM, respectively. HIV-1 integrase inhibitor 12 exhibits metabolic stability and Caco-2 permeability, and good pharmacokinetic characteristics with good bioavailability (64%) and low clearance (0.16 L/hr/kg) in rats .
    HIV-1 integrase inhibitor 12
  • HY-170933
    SGK1-IN-6

    		SGK Cancer
    SGK1-IN-6 (compound 12f) is a potent SGK1 inhibitor with an IC50 of 0.39 μM. SGK1-IN-6 suppresses tumor growth in the PC3 xenograft model in BALB/c nude mice without inducing any observable toxicity .
    SGK1-IN-6
  • HY-170773
    Mtb-IN-9

    		Bacterial Infection
    Mtb-IN-9 (Compound M1) is a specific Mtb inhibitor that inhibits MtbFadD32 and MtbFadD28 activity. Mtb-IN-9 curtails the Mtb survival in infected macrophages and reduces Mtb burden and tubercular granulomas in a chronic infection model of BALB/c mice. Mtb-IN-9 is promising for research of tuberculosis .
    Mtb-IN-9
  • HY-171185
    CP-611,781

    		Drug Metabolite Others
    CP-611,781 is a diol metabolite of ezlopitant alkene (CJ-12,458). In human liver microsomes, the apparent KM value of 5.4 μM for the formation of CP-611,781 .
    CP-611,781
  • HY-150611
    EGFR-IN-70

    		EGFR Cancer
    EGFR-IN-70 (compound 18j) is a potent EGFR inhibitor with IC50 values of 23.6 and 307.5 nM for EGFR LR/TM/CS and EGFR WT, respectively. EGFR-IN-70 has anti-proliferative activity and suppresses phosphorylation of the EGFR. EGFR-IN-70 can be used for cancer research .
    EGFR-IN-70
  • HY-149359
    IHMT-IDH1-053

    		Isocitrate Dehydrogenase (IDH) Cancer
    IHMT-IDH1-053 (compound 16) is a highly selectivity and irreversible IDH1-mutant inhibitor with an IC50 of 4.7 nM for IDH1 R132H. IHMT-IDH1-053 displays high selectivity against IDH1 mutants over IDH1 wt and IDH2 wt/mutants. IHMT-IDH1-053 inhibits 2-hydroxyglutarate (2-HG) production in IDH1 R132H mutant transfected 293T cells (IC50=28 nM). IHMT-IDH1-053 binds to the IDH1 R132H protein in the allosteric pocket adjacent to the NAPDH binding pocket through a covalent bond with residue Cys269. IHMT-IDH1-053 inhibits the proliferation of HT1080 cell line and primary AML cells which both bear IDH1 R132 mutants .
    IHMT-IDH1-053
  • HY-100028
    AT-130
    1 Publications Verification

    		 HBV DNA/RNA Synthesis Infection Cancer
    AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells .
    AT-130
  • HY-146710
    RET-IN-16

    		RET Cancer
    RET-IN-16 is a potent and selective RET inhibitor with IC50s of 3.98 nM, 8.42 nM, 15.05 nM, 7.86 nM, 5.43 nM and 8.86 nM for RET(WT), RET(M918T), RET(V804L), RET(V804M), RET-CCDC6 and RET-KIF5B, respectively. RET-IN-16 has anticancer effects .
    RET-IN-16
  • HY-146505
    Tubulin polymerization-IN-6

    		Microtubule/Tubulin Apoptosis Reactive Oxygen Species (ROS) Cancer
    Tubulin polymerization-IN-6 (compound 5f) is a potent tubulin polymerization inhibitor, with an IC50 of 1.09 μM. Tubulin polymerization-IN-6 inhibits cell migration and tube formation and contributes to the anti-angiogenesis. Tubulin polymerization-IN-6 can greatly inhibit tumor growth on HT29 xenograft Balb/c nude mice .
    Tubulin polymerization-IN-6
  • HY-149206
    HPK1-IN-33

    		MAP4K Cancer
    HPK1-IN-33 (compound 21) is a potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitor with a Ki value of 1.7 nM. HPK1-IN-33 inhibits the produce of IL-2 with EC50s of 286, >10000 nM in Jurkat WT and Jurkat HPK1 KO cells, respectively .
    HPK1-IN-33
  • HY-132229
    LPM4870108

    		Trk Receptor Cancer
    LPM4870108 is a potent and orally active pan-Trk (WT and MT) inhibitor, with IC50s of 0.2 nM, 2.4 nM, 3.5 nM and 2.3 nM for TrkC, TrkA, TrkA G595R and TrkA G667C, respectively. LPM4870108 shows selectivity for Trk over ALK (IC50=182 nM). LPM4870108 exhibits anti-tumor activity .
    LPM4870108
  • HY-172787
    FGFR4-IN-23

    		FGFR Akt AMPK Cancer
    FGFR4-IN-23 (compound 48c) is a FGFR4 inhibitor with an IC50 value of 2.9 nM against FGFR4 WT kinase. FGFR4-IN-23 inhibits the phosphorylation of FGFR4, AKT and MAPK .
    FGFR4-IN-23
  • HY-149401
    EGFR-IN-82

    		EGFR Cancer
    EGFR-IN-82 (Cmpound 8a) is a potent and orally active EGFR inhibitor with IC50 values of 0.09 and 0.06 nM for EGFR L858R/T790M/C797S and EGFR Del19/T790M/C797S, respectively. EGFR-IN-82 has no significant effect on EGFR WT. EGFR-IN-82 has anti-proliferative activity and inhibits tumor formation in nude mice. EGFR-IN-82 can be used in non-small cell lung cancer research .
    EGFR-IN-82
  • HY-N14910
    Actiketal

    		Antibiotic Bacterial Infection
    Actiketal is a glutarimide antibiotic that inhibits the incorporation of [ 3H]thymidine into EGF-stimulated Balb/MK cells .
    Actiketal
  • HY-N10264
    Avrainvillamide

    (+)-Avrainvillamide; cJ-17,665

    		 Antibiotic Infection Cancer
    Avrainvillamide ((+)-Avrainvillamide) is a naturally occurring alkaloid with antiproliferative effects, binds to the nuclear chaperone nucleophosmin, a proposed oncogenic protein that is overexpressed in many different human tumors. Avrainvillamide affects cell biology both by directly binding NPM1 and Crm1 as well as by inhibiting the association of these proteins with certain native cellular partners. Avrainvillamide, an antibiotic, inhibits growth of multi-agent resistant Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis, with MICs of 12.5, 12.5 and 25 μg/ml, respectively .
    Avrainvillamide
  • HY-151155
    ALK-IN-23

    		Anaplastic lymphoma kinase (ALK) Cancer
    ALK-IN-23 is a potent ALK inhibitor with IC50 values of 1.6 nM, 0.71 nM and 1.3 nM for ALK WT, ALK L1196M and ALK G1202R. ALK-IN-23 can block cell cycle in G2 phase and induce apoptosis. ALK-IN-23 inhibits cancer cell migration and colony formation in vitro. ALK-IN-23 exhibits antitumor activity in H2228 xenograft nude mice model with hypotoxicity .
    ALK-IN-23
  • HY-121845
    4-Br-Bnlm

    		HSP Metabolic Disease
    4-Br-Bnlm is a selective inhibitor of glucose-regulated protein 94 (Grp94) with an EC50 value of 0.96 µM. 4-Br-Bnlm reduces the levels of mutant myocilin proteins as well as wild-type myocilin misfold in cells. 4-Br-Bnlm promotes the clearance of toxic formsof myocilin and reduces myocilin toxicity .
    4-Br-Bnlm

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: